Total Payments
$185,344
2024 Payments
$16,980
Companies
18
Transactions
216
Medicare Patients
5,805
Medicare Billing
$537,937
Payment Breakdown by Category
Consulting$155,130 (83.7%)
Travel$11,092 (6.0%)
Other$7,375 (4.0%)
Research$6,892 (3.7%)
Food & Beverage$4,827 (2.6%)
Education$27.61 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $155,130 | 55 | 83.7% |
| Travel and Lodging | $11,092 | 48 | 6.0% |
| Unspecified | $6,892 | 18 | 3.7% |
| Food and Beverage | $4,827 | 88 | 2.6% |
| Honoraria | $4,000 | 1 | 2.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,375 | 4 | 1.8% |
| Education | $27.61 | 2 | 0.0% |
Payments by Type
General
$178,452
198 transactions
Research
$6,892
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $61,484 | 62 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $45,637 | 64 | $0 (2022) |
| UCB SA | $26,608 | 21 | $0 (2024) |
| Neurelis, Inc. | $21,825 | 6 | $0 (2021) |
| UCB, Inc. | $9,275 | 24 | $0 (2024) |
| Marinus Pharmaceuticals, Inc. | $7,500 | 2 | $0 (2024) |
| CATALYST PHARMACEUTICALS, INC. | $4,776 | 4 | $0 (2024) |
| EMD Serono Research & Development Institute, Inc. | $3,280 | 1 | $0 (2024) |
| Biogen, Inc. | $2,972 | 14 | $0 (2020) |
| AQUESTIVE THERAPEUTICS, INC. | $1,020 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,980 | 7 | Marinus Pharmaceuticals, Inc. ($5,000) |
| 2023 | $18,668 | 11 | UCB SA ($8,814) |
| 2022 | $16,288 | 16 | UCB, Inc. ($5,182) |
| 2021 | $16,545 | 6 | Neurelis, Inc. ($9,450) |
| 2020 | $39,284 | 20 | Eisai Inc. ($14,640) |
| 2019 | $29,248 | 61 | EISAI INC. ($14,871) |
| 2018 | $20,839 | 24 | Jazz Pharmaceuticals Inc. ($11,776) |
| 2017 | $27,493 | 71 | Jazz Pharmaceuticals Inc. ($13,325) |
All Payment Transactions
216 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $186.22 | General |
| 08/02/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,570.00 | General |
| 07/29/2024 | Eisai Inc. | Fycompa (Drug) | Consulting Fee | Cash or cash equivalent | $2,610.00 | General |
| Category: Neurology | ||||||
| 06/14/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Education | Cash or cash equivalent | $14.00 | General |
| Category: NEUROLOGY | ||||||
| 04/03/2024 | Eisai Inc. | Fycompa (Drug) | Consulting Fee | Cash or cash equivalent | $2,320.00 | General |
| Category: Neurology | ||||||
| 03/11/2024 | EMD Serono Research & Development Institute, Inc. | — | — | Cash or cash equivalent | $3,280.00 | Research |
| Study: Enpatoran Human Mass Balance and Absolute Bioavailability Study | ||||||
| 03/06/2024 | Marinus Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 12/02/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $114.58 | General |
| 10/20/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,570.00 | General |
| 09/30/2023 | Catalyst Pharmaceuticals, Inc. | FYCOMPA (Drug) | Honoraria | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROLOGY | ||||||
| 09/30/2023 | Catalyst Pharmaceuticals, Inc. | FYCOMPA (Drug) | Travel and Lodging | Cash or cash equivalent | $544.05 | General |
| Category: NEUROLOGY | ||||||
| 09/30/2023 | Catalyst Pharmaceuticals, Inc. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $218.40 | General |
| Category: NEUROLOGY | ||||||
| 08/29/2023 | Eisai Inc. | Fycompa (Drug) | Consulting Fee | Cash or cash equivalent | $2,320.00 | General |
| Category: Neurology | ||||||
| 08/04/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,204.00 | General |
| 04/28/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| 04/26/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $77.31 | General |
| 02/01/2023 | Marinus Pharmaceuticals, Inc. | ZTALMY (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: SEIZURE DISORDERS | ||||||
| 01/11/2023 | Sumitomo Pharma America, Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $79.17 | General |
| Category: CNS | ||||||
| 12/09/2022 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 12/08/2022 | EISAI INC. | Fycompa (Drug) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: Neurology | ||||||
| 12/03/2022 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $133.43 | General |
| 11/17/2022 | UCB, Inc. | Fintepla (Drug) | Consulting Fee | Cash or cash equivalent | $3,619.00 | General |
| Category: Neurology | ||||||
| 11/17/2022 | UCB, Inc. | Fintepla (Drug) | Travel and Lodging | Cash or cash equivalent | $97.32 | General |
| Category: Neurology | ||||||
| 10/29/2022 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $36.65 | General |
| Category: Neurology | ||||||
| 10/29/2022 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $36.65 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Enpatoran Human Mass Balance and Absolute Bioavailability Study | EMD Serono Research & Development Institute, Inc. | $3,280 | 1 |
| Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | Biogen, Inc. | $1,972 | 13 |
| Safety of adjunctive lacosamide in patients with primary generalized tonic-clonic seizures (PGTCS) and patients with focal seizures: pooled data for pediatrics and adults | UCB, Inc. | $420.00 | 1 |
| Safety of adjunctive lacosamide in patients with primary generalized tonic-clonic seizures PGTCS and patients with focal seizures pooled data for pediatrics and adults | UCB, Inc. | $420.00 | 1 |
| Safety of adjunctive lacosamide in patients with primary generalized tonic-clonicseizures and patients with focal seizures pooled data for pediatrics and adults | UCB, Inc. | $400.00 | 1 |
| Safety of adjunctive lacosamide in patients with primary generalized tonic-clonicseizures and patients with focal seizures: pooled data for pediatrics and adults | UCB, Inc. | $400.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,259 | 2,228 | $677,050 | $121,157 |
| 2022 | 19 | 1,406 | 2,404 | $705,782 | $125,157 |
| 2021 | 17 | 1,509 | 2,781 | $749,581 | $141,325 |
| 2020 | 20 | 1,631 | 2,694 | $824,930 | $150,297 |
Total Patients
5,805
Total Services
10,107
Medicare Billing
$537,937
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 103 | 220 | $182,820 | $32,581 | 17.8% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2023 | 197 | 1,010 | $102,010 | $24,305 | 23.8% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2023 | 162 | 173 | $75,255 | $14,795 | 19.7% |
| 95861 | Needle measurement of electrical activity in arm or leg muscles, 2 extremities | Facility | 2023 | 173 | 182 | $64,064 | $10,762 | 16.8% |
| 95938 | Placement of skin electrodes and measurement of stimulated sites on arms and legs | Facility | 2023 | 163 | 174 | $28,884 | $5,766 | 20.0% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 51 | 52 | $36,816 | $4,107 | 11.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 36 | 38 | $13,072 | $3,476 | 26.6% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 35 | 36 | $25,704 | $3,199 | 12.4% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2023 | 26 | 27 | $14,499 | $2,699 | 18.6% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 30 | 30 | $21,240 | $2,649 | 12.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 40 | 43 | $10,965 | $2,506 | 22.9% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 25 | 25 | $17,850 | $2,330 | 13.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 28 | $7,140 | $1,849 | 25.9% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2023 | 61 | 61 | $39,345 | $1,667 | 4.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $6,630 | $1,650 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $8,330 | $1,638 | 19.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 36 | 36 | $6,372 | $1,531 | 24.0% |
| 51785 | Needle measurement and recording of electrical activity of muscles at bladder and bowel openings | Facility | 2023 | 19 | 19 | $5,396 | $1,298 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $3,784 | $1,051 | 27.8% |
| 92653 | Evaluation of brain response to sound for diagnosis of nervous system disorders with interpretation and report | Facility | 2023 | 12 | 12 | $3,780 | $765.60 | 20.3% |
| 95867 | Needle measurement of electrical activity in muscles on side of body | Facility | 2023 | 17 | 17 | $3,094 | $533.46 | 17.2% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2022 | 204 | 1,104 | $111,504 | $27,023 | 24.2% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2022 | 85 | 167 | $138,777 | $24,897 | 17.9% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2022 | 185 | 189 | $82,215 | $16,996 | 20.7% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2022 | 143 | 143 | $101,244 | $11,990 | 11.8% |
About Dr. Aatif Husain, M.D
Dr. Aatif Husain, M.D is a Neurology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497837595.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aatif Husain, M.D has received a total of $185,344 in payments from pharmaceutical and medical device companies, with $16,980 received in 2024. These payments were reported across 216 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($155,130).
As a Medicare-enrolled provider, Husain has provided services to 5,805 Medicare beneficiaries, totaling 10,107 services with total Medicare billing of $537,937. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Durham, NC
- Active Since 10/19/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1497837595
Products in Payments
- Fycompa (Drug) $52,142
- VALTOCO (Drug) $21,825
- Xyrem (Drug) $20,113
- XYREM (Drug) $12,745
- Vimpat (Drug) $8,598
- XYWAV (Drug) $6,825
- Fintepla (Drug) $4,933
- Dayvigo (Drug) $4,800
- FYCOMPA (Drug) $4,776
- ZTALMY (Drug) $2,500
- TYSABRI (Biological) $1,972
- APTIOM (Drug) $440.05
- ACTIVA (Device) $246.76
- Briviact (Drug) $216.45
- ONFI (Drug) $108.10
- OXTELLAR XR (Drug) $27.97
- DreamStat Cpap Auto (Device) $21.02
- VNS Therapy (Device) $17.90
- Cenobamate (Drug) $13.61
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Durham
Mark Skeen, M.d, M.D
Neurology — Payments: $770,195
Neurology $770,195
Dr. Kevin Kahn, Md, MD
Neurology — Payments: $662,344
Neurology $662,344
Dr. Alan Finkel, Md, MD
Neurology — Payments: $405,703
Neurology $405,703
Natalia Gonzalez, Md, MD
Neurology — Payments: $219,812
Neurology $219,812
Dr. Anne Calhoun, Md, MD
Neurology — Payments: $203,020
Neurology $203,020
Dr. Jeffrey Guptill, M.d, M.D
Neurology — Payments: $191,526
Neurology $191,526